Monitoring cisplatin-induced ototoxicity.
Abstract Introduction and objective: The ototoxic damage goes unnoticed to disabling levels, being justified to apply control for its early detection procedures, make it possible to a therapeutic change and if necessary, a speech and auditory rehabilitation. The objective of this study will consist to present Protocol we did at the Hospital Clínico Universitario de Valladolid for the follow-up of the patients treated with cisplatin. Method: Ototoxicity monitoring means serially collect hearing thresholds. It is identified on a visit if hearing has worsened in some ear. The comparison allows to detect the change and indicate if it is significant or not in relation to some criteria. We will also evaluate the occurrence of vestibular damage. As auditory monitoring procedures, we will use high frequency audiometry and acoustic oto-emissions. Results: After giving informed consent and a brief medical history we started with baseline assessment of hearing, prior to treatment, continuing with periodic reviews before each cycle. If any change is detected it is reported to the physician and the patient. To grade the ototoxicity, we apply the Brock and Chang criteria. We maintain post-treatment control. Discussion and conclusion: The incidence of ototoxicity of cisplatin is unknown in our country and it is not possible to predict which patients will experience. The increase in the survival rate for cancer involves improving comorbidity, which in the case of its early ototoxicity supposed to find the best solutions to restore the quality of life of patient’s detection.
- Referencias
- Cómo citar
- Del mismo autor
- Métricas
American Academy of Audiology Position Statement and Clinical Practice Guidelines. Ototoxicity Monitoring. October 2009. Disponible en: https://www.audiology.org/publications-resources/document-library/ototoxicity-monitoring. [Citado el 29 de julio de 2017].
American Speech-Language-Hearing Association. Audiologic management of individuals receiving cochleotoxic drug therapy. ASHA 1994;(suppl 12)36:11-9.
Arora R, Thakur JS, Azad RK, Mohindroo NK, Sharma DR, Seam RK. Cisplatin-based chemotherapy: Add high-frequency audiometry in the regimen. Indian J Cancer. 2009;46(4):311-7. https://doi.org/10.4103/0019-509X.55551 - PMid:19749461
Brock PR, Bellman SC, Yeomans EC, Pinkerton CR, Pritchard J. Cisplatin ototoxicity in children: a practical grading system. Med Pediatr Oncol. 1991;19(4):295-300. https://doi.org/10.1002/mpo.2950190415 - PMid:2056973
Campbell K. Pharmacology and ototoxicity for audiologists. 1st ed. New York: Thomson Delmar Learning, 2007; p. 416. PMid:17958209
Chang KW, Chinosornvatana N. Practical grading system for evaluating cisplatin ototoxicity in children. J Clin Oncol. 2010;28(10):1788-95. https://doi.org/10.1200/JCO.2009.24.4228 - PMid:20194861
Coradini PP, Cigana L, Selistre SG, Rosito LS, Brunetto AL. Ototoxicity from cisplatin therapy in childhood cancer. J Pediatr Hematol Oncol. 2007;29(6):355-60.
https://doi.org/10.1097/MPH.0b013e318059c220 - PMid:17551394
Crundwell G, Gomersall P, Baguley DM. Ototoxicity (cochleotoxicity) classifications: A review. Int J Audiol. 2016;55(2):65-74.
https://doi.org/10.3109/14992027.2015.1094188 - PMid:26618898
Dalton D, Cruickshanks K, Klein B, Klein R, Wiley T, Nondahl D. The impact of hearing loss on quality of life in older adults. Gerontologist 2003; 43: 661-8.
https://doi.org/10.1093/geront/43.5.661 - PMid:14570962
Dille MF, Wilmington D, McMillan GP, Helt W, Fausti SA, Konrad-Martin D. Development and validation of a cisplatin dose-ototoxicity model. J Am Acad Audiol 2012; 23(7): 510-21. https://doi.org/10.3766/jaaa.23.7.3 - PMid:22992258 PMCid:PMC5549622
Dulon D, Mosnier I, Bouccara D. Ototoxicité médicamenteuse. EMC–Oto-rhino-laryngologie 2012; 7(4): 20-184-B-10. p.12.
Durrant J, Palmer C, Lunner T. Analysis of counted behaviors in a single-subject design: Modeling of hearing-aid intervention in hearing-aid patients with Alzheimer's disease. Int J Audiol 2005; 44: 31-8. https://doi.org/10.1080/14992020400022637 - PMid:15796100
Einarsson EJ, Petersen H, Wiebe T, Fransson PA, Magnusson M, Moëll C. Severe difficulties with word recognition in noise after platinum chemotherapy in childhood, and improvements with open-fitting hearing-aids. Int J Audiol 2011; 50(10): 642-51. https://doi.org/10.3109/14992027.2011.585667 - PMid:21812630
Fausti SA, Larson VD, Noffsinger D, Wilson RH, Phillips DS, Fowler CG. High-frequency audiometric monitoring strategies for early detection of ototoxicity. Ear Hear 1994; 15(3): 232-9. https://doi.org/10.1097/00003446-199406000-00004 - PMid:8076721
Fausti SA, Wilmington DJ, Helt PV, Helt WJ, Konrad-Martin D. Hearing health and care: the need for improved hearing loss prevention and hearing conservation practices. J Rehabil Res Dev. 2005;42(4 Suppl 2):45-62. https://doi.org/10.1682/JRRD.2005.02.0039 - PMid:16470464
Gorga MP, Neelsy ST, Johnson TA, Dierking DM, Garner CA. Distortion-Product Otoacoustic emissions in relation to hearing loss. In: Robinette MS, Glattke TJ, editors. Otoacoustic Emissions. Clinical Applications. Third ed. New York, Stuttgart: Thieme; 2007. p. 197-225.
Halmagyi GM, Curthoys IS. A clinical sign of canal paresis. Arch Neurol 1988; 45: 737-9. https://doi.org/10.1001/archneur.1988.00520310043015
Jerger J. Early detection of ototoxicity. J Am Acad Audiol 2003; 14(5): 230. PMid:12956305
Knight KR, Kraemer DF, Winter C, Neuwelt EA. Early changes in auditory function as a result of platinum chemotherapy: use of extended high-frequency audiometry and evoked distortion product otoacoustic emissions. J Clin Oncol. 2007;25(10):1190-5. https://doi.org/10.1200/JCO.2006.07.9723 - PMid:17401008
Konrad-Martin D, James KE, Gordon JS, Reavis KM, Phillips DS, Bratt GW, Fausti SA. Evaluation of audiometric threshold shift criteria for ototoxicity monitoring. J Am Acad Audiol. 2010 May; 21(5):301-14. https://doi.org/10.3766/jaaa.21.5.3 - PMid:20569665 PMCid:PMC5588921
Konrad-Martin D, Reavis KM, McMillan GP, Dille MF. Multivariate DPOAE metrics for identifying changes in hearing: perspectives from ototoxicity monitoring. Int J Audiol 2012; 51 Suppl 1: S51-62. https://doi.org/10.3109/14992027.2011.635713 - PMid:22264063 PMCid:PMC5588874
Landier W. Ototoxicity and cancer therapy. Cancer. 2016;122(11):1647-58. https://doi.org/10.1002/cncr.29779 - PMid:26859792
Lonsbury-Martin BL, Martin GK. Distortion-Product Otoacoustic emissions in populations with normal hearing sensitivity. In: Robinette MS, Glattke TJ, editors. Otoacoustic Emissions. Clinical Applications. Third ed. New York, Stuttgart: Thieme; 2007. p. 107-30.
Mukherjea D, Rybak LP. Pharmacogenomics of cisplatin-induced ototoxicity. Pharmacogenomics 2011; 12(7): 1039-50.
https://doi.org/10.2217/pgs.11.48 - PMid:21787192 PMCid:PMC3217465
Reavis KM, McMillan G, Austin D, Gallun F, Fausti SA, Gordon JS, Helt WJ, Konrad-Martin D. Distortion-Product Otoacoustic Emission Test Performance for Ototoxicity Monitoring. Ear Hear 2011; 32 (1): 61-74. PMid:20625302 PMCid:PMC5588870
Robinette MS, Glattke TJ. Otoacoustic emissions. Clinical applications. Third ed. New York: Thieme Medical Publishers; 2007.
Rybak LP, Mukherjea D, Jajoo S, Ramkumar V. Cisplatin ototoxicity and protection: clinical and experimental studies. Tohoku J Exp Med. 2009;219(3):177-86.
https://doi.org/10.1620/tjem.219.177 - PMid:19851045 PMCid:PMC2927105
Stelmachowicz PG, Pittman AL, Hoover BM, Lewis DE, Moeller MP. The importance of high-frequency audibility in the speech and language development of children with hearing loss. Arch Otolaryngol Head Neck Surg 2004; 130 (5): 556-62. https://doi.org/10.1001/archotol.130.5.556 - PMid:15148176
Waissbluth S, Daniel SJ. Cisplatin induced ototoxicity: transporters playing a role in cisplatin toxicity. Hear Res 2013; 1-9.
https://doi.org/10.1016/j.heares.2013.02.002
Wang J, Lloyd R, Chaix B, Puel JL. The biological of drug-induced hearing loss. ENT audiology news 2012; 21(1): 62-4.
Warrier R, Chauhan A, Davluri M, Tedesco SL, Nadell J, Craver R. Cisplatin and cranial irradiation-related hearing loss in children. Ochsner J 2012; 12(3): 191-6.
PMid:23049454 PMCid:PMC3448239
Yilmaz S, Oktem F, Karaman E. Detection of cisplatin-induced ototoxicity with transient evoked otoacoustic emission test before pure tone audiometer. Eur Arch Otorhinolaryngol 2010; 267(7): 1041-4. https://doi.org/10.1007/s00405-009-1165-7 - PMid:19946777
American Speech-Language-Hearing Association. Audiologic management of individuals receiving cochleotoxic drug therapy. ASHA 1994;(suppl 12)36:11-9.
Arora R, Thakur JS, Azad RK, Mohindroo NK, Sharma DR, Seam RK. Cisplatin-based chemotherapy: Add high-frequency audiometry in the regimen. Indian J Cancer. 2009;46(4):311-7. https://doi.org/10.4103/0019-509X.55551 - PMid:19749461
Brock PR, Bellman SC, Yeomans EC, Pinkerton CR, Pritchard J. Cisplatin ototoxicity in children: a practical grading system. Med Pediatr Oncol. 1991;19(4):295-300. https://doi.org/10.1002/mpo.2950190415 - PMid:2056973
Campbell K. Pharmacology and ototoxicity for audiologists. 1st ed. New York: Thomson Delmar Learning, 2007; p. 416. PMid:17958209
Chang KW, Chinosornvatana N. Practical grading system for evaluating cisplatin ototoxicity in children. J Clin Oncol. 2010;28(10):1788-95. https://doi.org/10.1200/JCO.2009.24.4228 - PMid:20194861
Coradini PP, Cigana L, Selistre SG, Rosito LS, Brunetto AL. Ototoxicity from cisplatin therapy in childhood cancer. J Pediatr Hematol Oncol. 2007;29(6):355-60.
https://doi.org/10.1097/MPH.0b013e318059c220 - PMid:17551394
Crundwell G, Gomersall P, Baguley DM. Ototoxicity (cochleotoxicity) classifications: A review. Int J Audiol. 2016;55(2):65-74.
https://doi.org/10.3109/14992027.2015.1094188 - PMid:26618898
Dalton D, Cruickshanks K, Klein B, Klein R, Wiley T, Nondahl D. The impact of hearing loss on quality of life in older adults. Gerontologist 2003; 43: 661-8.
https://doi.org/10.1093/geront/43.5.661 - PMid:14570962
Dille MF, Wilmington D, McMillan GP, Helt W, Fausti SA, Konrad-Martin D. Development and validation of a cisplatin dose-ototoxicity model. J Am Acad Audiol 2012; 23(7): 510-21. https://doi.org/10.3766/jaaa.23.7.3 - PMid:22992258 PMCid:PMC5549622
Dulon D, Mosnier I, Bouccara D. Ototoxicité médicamenteuse. EMC–Oto-rhino-laryngologie 2012; 7(4): 20-184-B-10. p.12.
Durrant J, Palmer C, Lunner T. Analysis of counted behaviors in a single-subject design: Modeling of hearing-aid intervention in hearing-aid patients with Alzheimer's disease. Int J Audiol 2005; 44: 31-8. https://doi.org/10.1080/14992020400022637 - PMid:15796100
Einarsson EJ, Petersen H, Wiebe T, Fransson PA, Magnusson M, Moëll C. Severe difficulties with word recognition in noise after platinum chemotherapy in childhood, and improvements with open-fitting hearing-aids. Int J Audiol 2011; 50(10): 642-51. https://doi.org/10.3109/14992027.2011.585667 - PMid:21812630
Fausti SA, Larson VD, Noffsinger D, Wilson RH, Phillips DS, Fowler CG. High-frequency audiometric monitoring strategies for early detection of ototoxicity. Ear Hear 1994; 15(3): 232-9. https://doi.org/10.1097/00003446-199406000-00004 - PMid:8076721
Fausti SA, Wilmington DJ, Helt PV, Helt WJ, Konrad-Martin D. Hearing health and care: the need for improved hearing loss prevention and hearing conservation practices. J Rehabil Res Dev. 2005;42(4 Suppl 2):45-62. https://doi.org/10.1682/JRRD.2005.02.0039 - PMid:16470464
Gorga MP, Neelsy ST, Johnson TA, Dierking DM, Garner CA. Distortion-Product Otoacoustic emissions in relation to hearing loss. In: Robinette MS, Glattke TJ, editors. Otoacoustic Emissions. Clinical Applications. Third ed. New York, Stuttgart: Thieme; 2007. p. 197-225.
Halmagyi GM, Curthoys IS. A clinical sign of canal paresis. Arch Neurol 1988; 45: 737-9. https://doi.org/10.1001/archneur.1988.00520310043015
Jerger J. Early detection of ototoxicity. J Am Acad Audiol 2003; 14(5): 230. PMid:12956305
Knight KR, Kraemer DF, Winter C, Neuwelt EA. Early changes in auditory function as a result of platinum chemotherapy: use of extended high-frequency audiometry and evoked distortion product otoacoustic emissions. J Clin Oncol. 2007;25(10):1190-5. https://doi.org/10.1200/JCO.2006.07.9723 - PMid:17401008
Konrad-Martin D, James KE, Gordon JS, Reavis KM, Phillips DS, Bratt GW, Fausti SA. Evaluation of audiometric threshold shift criteria for ototoxicity monitoring. J Am Acad Audiol. 2010 May; 21(5):301-14. https://doi.org/10.3766/jaaa.21.5.3 - PMid:20569665 PMCid:PMC5588921
Konrad-Martin D, Reavis KM, McMillan GP, Dille MF. Multivariate DPOAE metrics for identifying changes in hearing: perspectives from ototoxicity monitoring. Int J Audiol 2012; 51 Suppl 1: S51-62. https://doi.org/10.3109/14992027.2011.635713 - PMid:22264063 PMCid:PMC5588874
Landier W. Ototoxicity and cancer therapy. Cancer. 2016;122(11):1647-58. https://doi.org/10.1002/cncr.29779 - PMid:26859792
Lonsbury-Martin BL, Martin GK. Distortion-Product Otoacoustic emissions in populations with normal hearing sensitivity. In: Robinette MS, Glattke TJ, editors. Otoacoustic Emissions. Clinical Applications. Third ed. New York, Stuttgart: Thieme; 2007. p. 107-30.
Mukherjea D, Rybak LP. Pharmacogenomics of cisplatin-induced ototoxicity. Pharmacogenomics 2011; 12(7): 1039-50.
https://doi.org/10.2217/pgs.11.48 - PMid:21787192 PMCid:PMC3217465
Reavis KM, McMillan G, Austin D, Gallun F, Fausti SA, Gordon JS, Helt WJ, Konrad-Martin D. Distortion-Product Otoacoustic Emission Test Performance for Ototoxicity Monitoring. Ear Hear 2011; 32 (1): 61-74. PMid:20625302 PMCid:PMC5588870
Robinette MS, Glattke TJ. Otoacoustic emissions. Clinical applications. Third ed. New York: Thieme Medical Publishers; 2007.
Rybak LP, Mukherjea D, Jajoo S, Ramkumar V. Cisplatin ototoxicity and protection: clinical and experimental studies. Tohoku J Exp Med. 2009;219(3):177-86.
https://doi.org/10.1620/tjem.219.177 - PMid:19851045 PMCid:PMC2927105
Stelmachowicz PG, Pittman AL, Hoover BM, Lewis DE, Moeller MP. The importance of high-frequency audibility in the speech and language development of children with hearing loss. Arch Otolaryngol Head Neck Surg 2004; 130 (5): 556-62. https://doi.org/10.1001/archotol.130.5.556 - PMid:15148176
Waissbluth S, Daniel SJ. Cisplatin induced ototoxicity: transporters playing a role in cisplatin toxicity. Hear Res 2013; 1-9.
https://doi.org/10.1016/j.heares.2013.02.002
Wang J, Lloyd R, Chaix B, Puel JL. The biological of drug-induced hearing loss. ENT audiology news 2012; 21(1): 62-4.
Warrier R, Chauhan A, Davluri M, Tedesco SL, Nadell J, Craver R. Cisplatin and cranial irradiation-related hearing loss in children. Ochsner J 2012; 12(3): 191-6.
PMid:23049454 PMCid:PMC3448239
Yilmaz S, Oktem F, Karaman E. Detection of cisplatin-induced ototoxicity with transient evoked otoacoustic emission test before pure tone audiometer. Eur Arch Otorhinolaryngol 2010; 267(7): 1041-4. https://doi.org/10.1007/s00405-009-1165-7 - PMid:19946777
Sánchez-Martínez, A., Benito-Orejas, J. I., Tavárez-Rodríguez, J. J., Hernández-Santos, M. L., Morais-Pérez, D., & Soto-Prado, D. (2018). Monitoring cisplatin-induced ototoxicity. Revista ORL, 9(1), 25–33. https://doi.org/10.14201/orl.16774
Most read articles by the same author(s)
- José Ignacio Benito-Orejas, III Otoneurological meeting of Otorhinolaringology Society of Cas-tilla and León, Cantabria and La Rioja (Spain). Zamora, March 17, 2018 , Revista ORL: Vol. 9 No. 2 (2018)
- Jaime Santos-Pérez, Ana Fernández-Rodríguez, Ana Sánchez-Martínez, MANAGEMENT OF THE PATIENT WITH RHINOSINUSITIS AND NASAL POLYPS. FROM THE GUIDES TO THE CLINICAL PRACTICE , Revista ORL: Segovia 2018
- Carlos Miguel Salvador-Ramírez, Nuria Mesuro-Domínguez, Juan José Tavarez-Rodríguez, María de Lourdes Hernández-De los Santos, Marcela Adriana Durán-Álvarez, Neuroendocrine Carcinoma of Supraglottic , Revista ORL: Vol. 13 No. S2 (2022): XXVIII Congreso de la Sociedad Otorrinolaringológica de Castilla y León, Cantabria y La Rioja Valladolid 2, 3 y 4 de junio de 2022
- Juan Losada-Campa, José Ignacio Benito-Orejas, María Álvarez-Álvarez, Mariana González-Sosto, Jaime Santos-Pérez , Maria Fe Muñoz-Moreno, Otological Follow-up in Children with Down Syndrome , Revista ORL: Vol. 13 No. S2 (2022): XXVIII Congreso de la Sociedad Otorrinolaringológica de Castilla y León, Cantabria y La Rioja Valladolid 2, 3 y 4 de junio de 2022
- María Álvarez-Álvarez, José Ignacio Benito-Orejas, José Antonio Cámara-Arnaz, María Consolación Martín-Pascual, Mariana González-Sosto, Jaime Santos-Pérez, Audiovestibular Testing in Intravestibular Intralabyrinthine Schwannoma , Revista ORL: Vol. 13 No. S2 (2022): XXVIII Congreso de la Sociedad Otorrinolaringológica de Castilla y León, Cantabria y La Rioja Valladolid 2, 3 y 4 de junio de 2022
- Patricia Viveros-Díez, José Ignacio Benito-Orejas, Victoria Duque-Holguera, Beatriz Ramírez-Cano, María Antonia Carranza-Calleja, Jaime Santos-Pérez, Analysis of Risk Factors and Targeted Surveillance for Postnatal Hearing Loss During 25 Years of Hearing Screening , Revista ORL: Vol. 13 No. S2 (2022): XXVIII Congreso de la Sociedad Otorrinolaringológica de Castilla y León, Cantabria y La Rioja Valladolid 2, 3 y 4 de junio de 2022
- Victoria Duque-Holguera, José Ignacio Benito-Orejas, Laura Parra-Morais, Patricia Viveros-Díez, María Fe Muñoz-Moreno, Jaime Santos-Pérez, Title-Results of the Application of a Safety Protocol for Tracheostomized Patients Coming From a Critical Care Unit , Revista ORL: Vol. 13 No. S2 (2022): XXVIII Congreso de la Sociedad Otorrinolaringológica de Castilla y León, Cantabria y La Rioja Valladolid 2, 3 y 4 de junio de 2022
Downloads
Download data is not yet available.
+
−